BioNTech partners with CEPI to advance development of mpox vaccine, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech’s mRNA technology. BioNTech will initiate a early-to-mid stage trial for the vaccine BNT166 for the prevention of mpox., CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech’s mRNA technology. BioNTech will initiate a early-to-mid stage trial for the vaccine BNT166 for the prevention of mpox., , Read More